Threshold Pharmaceuticals Announces Presentation and Webcast at

Threshold Pharmaceuticals Announces Presentation and Webcast at
Lazard Capital Markets 9th Annual Healthcare Conference 
SOUTH SAN FRANCISCO, CA -- (Marketwire) -- 11/07/12 --   Threshold
Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that Barry
Selick, Ph.D., Threshold's Chief Executive Officer, will present a
company overview at the Lazard Capital Markets 9th Annual Healthcare
Conference at 2:00 p.m. ET on Wednesday, November 14, 2012. 
A live webcast of the presentation will be available under Webcasts
in the Investors section of www.thresholdpharm.com. A replay of the
presentation will be archived on the site for 30 days. 
About Threshold Pharmaceuticals
 Threshold is a biotechnology company
focused on the discovery and development of drugs targeting Tumor
Hypoxia, the low oxygen condition found in microenvironments of most
solid tumors as well as the bone marrows of some hematologic
malignancies. This approach offers broad potential to treat a variety
of cancers. By selectively targeting tumor cells, we are building a
pipeline of drugs that hold promise to be more effective and less
toxic to healthy tissues than conventional anticancer drugs. For
additional information, please visit our website
(www.thresholdpharm.com). 
Forward-Looking Statements
 Except for statements of historical fact,
the statements in this press release are forward-looking statements,
including statements regarding the potential therapeutic uses and
benefits of its product candidates. These statements involve risks
and uncertainties that can cause actual results to differ materially
from those in such forward-looking statements. Potential risks and
uncertainties include, but are not limited to, Threshold's ability to
enroll or complete its anticipated clinical trials, the time and
expense required to conduct such clinical trials and analyze data,
issues arising in the regulatory or manufacturing process and the
results of such clinical trials (including product safety issues and
efficacy results). Further information regarding these and other
risks is included under the heading "Risk Factors" in Threshold's
Quarterly Report on Form 10-Q, which has been filed with the
Securities and Exchange Commission on November 2, 2012 and is
available from the SEC's website (www.sec.gov) and on our website
(www.thresholdpharm.com) under the heading "Investors." We undertake
no duty to update any forward-looking statement made in this news
release. 
Contact
Laura Hansen, Ph.D.
Senior Director, Corporate Communications
Threshold Pharmaceuticals
Phone: 650-474-8206
E-mail: lhansen@thresholdpharm.com 
 
 
Press spacebar to pause and continue. Press esc to stop.